Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAGE-A10 peptide presented by HLA-A*02:01
- Molecular classification
- Peptide–MHC class I complex, Tumor-associated antigen peptide presented by human leukocyte antigen, Immunotherapy target
01
Overview
The MAGE-A10 peptide presented by HLA-A*02:01 is a tumor-associated antigen complex consisting of a 9-mer peptide (GLYDGMEHL) derived from melanoma antigen gene A10 and bound to the human leukocyte antigen HLA-A*02:01, an MHC class I molecule[1][3]. This complex is specifically recognized by engineered T-cell receptors designed for cancer immunotherapy, enabling targeted immune attack against tumor cells expressing MAGE-A10 in the context of HLA-A*02:01[1][3][4]. The structure and docking of the peptide in the HLA groove reveal unique stabilizing features, which influence TCR affinity and specificity, making it an important therapeutic target. The therapeutic approach is currently under investigation, with safety concerns including cross-reactivity and potential toxicity due to similar peptide motifs in non-tumor tissues[3][4].
- Other names
- MAGE-A10–HLA-A*02:01 complexMAGE-A10 9-mer peptide–HLA-A2MAGE-A10 epitope–HLA-A2 complex
02
Mechanism of action
Recognition and binding by engineered TCRs triggers cytotoxic T-cell activation against tumor cells expressing MAGE-A10 peptide in context of HLA-A*02:01
03
Biological functions
Antigen presentation to T cellsImmune recognition in cancerAdaptive immune response modulation
04
Disease associations
Cancer (notably melanoma and other solid tumors)
05
Safety considerations
Risk of off-target or cross-reactive TCR effectsPotential toxicity due to shared peptide motifs in healthy tissueImmunogenicity and cytokine release risks
06
Interacting drugs
Engineered T-cell receptor (TCR) therapeutics targeting MAGE-A10 presented by HLA-A*02:01
07
Biomarkers
Expression of MAGE-A10 peptide in tumor tissueHLA-A*02:01 positivity in patient tissue
Beyond the preview
Go deeper on MAGE-A10 peptide presented by HLA-A*02:01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-A10 peptide presented by HLA-A*02:01.